Epstein-Barr virus

Summary

Alias: Human herpesvirus 4, Epstein-Barr virus EBV, Human herpesvirus type 4, Epstein-Barr-virus EBV, EPV, HHV-4

Top Publications

  1. pmc The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species
    Bettina Gruhne
    Department of Cell and Molecular Biology, Karolinska Institutet, S 17177 Stockholm, Sweden
    Proc Natl Acad Sci U S A 106:2313-8. 2009
  2. doi The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC)
    Christopher W Dawson
    Birmingham Cancer Research UK Cancer Centre, School of Cancer Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom
    Semin Cancer Biol 22:144-53. 2012
  3. pmc PRA1 promotes the intracellular trafficking and NF-kappaB signaling of EBV latent membrane protein 1
    Hao Ping Liu
    Institute of Microbiology and Immunology, National Yang Ming University, Shih Pai, Taipei, Taiwan, Republic of China
    EMBO J 25:4120-30. 2006
  4. pmc Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines
    Lenka Skalska
    Section of Virology, Department of Medicine, Imperial College London, St Mary s Campus, London, United Kingdom
    PLoS Pathog 9:e1003187. 2013
  5. pmc An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link
    Gemma L Kelly
    Cancer Research UK Institute for Cancer Studies, The University of Birmingham, Edgbaston, Birmingham, United Kingdom
    PLoS Pathog 5:e1000341. 2009
  6. pmc Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes
    Liliana Terrin
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico IRCCS, National Cancer Institute, Via Franco Gallini 2, 33081 Aviano PN, Italy
    J Virol 82:10175-87. 2008
  7. pmc Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A
    Sizun Jiang
    Department of Medicine, Brigham and Women s Hospital, Program in Virology, Department of Microbiology and Immunobiology, and Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115
    Proc Natl Acad Sci U S A 111:421-6. 2014
  8. pmc Role for G-quadruplex RNA binding by Epstein-Barr virus nuclear antigen 1 in DNA replication and metaphase chromosome attachment
    Julie Norseen
    The Wistar Institute, Philadelphia, PA 19104, USA
    J Virol 83:10336-46. 2009
  9. pmc Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency
    Amanda R Robinson
    Department of Oncology McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706, USA
    J Virol 85:8940-53. 2011
  10. pmc Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex
    Hisae Matsuura
    Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 107:22641-6. 2010

Research Grants

  1. Ren Sun; Fiscal Year: 2016
  2. Chronic High EBV load and risk of PTLD in Pediatric Heart Transplant Patients
    Diana M Metes; Fiscal Year: 2013
  3. T Cell Immunity in Endemic Burkitt Lymphoma
    Ann M Moormann; Fiscal Year: 2012
  4. EBNA1 Functions Required in Burkitt's Lymphomas and Other Immortalized B-Cells
    AMBER TERESA WASHINGTON; Fiscal Year: 2012
  5. Anti-viral DC/NK interactions
    CHRISTIAN MUNZ; Fiscal Year: 2012
  6. THE ROLE OF EPSTEIN-BARR VIRUS EBNA1, LMP1 AND LMP2A PRO
    Richard Longnecker; Fiscal Year: 2003
  7. PREVENTION AND ANTIVIRAL TREATMENT FOR EBV LYMPHOMAGENESIS
    Joseph S Pagano; Fiscal Year: 2013
  8. Regulation of EBV Latency by Chromosome Conformation
    Italo Tempera; Fiscal Year: 2012
  9. Elliott D Kieff; Fiscal Year: 2016
  10. EBNA3C and tumor supressors
    Erle S Robertson; Fiscal Year: 2010

Patents

  1. Methods for the production of iPS cells using non-viral approach
  2. Method of detection and quantitation of a target nucleic acid in a test sample utilizing a novel positive control nucleic acid
  3. Novel Nucleic Acid Molecules
  4. HUMAN HERPESVIRUS TRIMERIC GLYCOPROTEIN B, PROTEIN COMPLEXES COMPRISING TRIMERIC GB AND THEIR USE AS VACCINES
  5. BIOMARKERS FOR ENDOMETRIOSIS
  6. MULTIMERIC FUSION PROTEIN VACCINE AND IMMUNOTHERAPEUTIC
  7. B-cell receptor complex binding proteins containing T-cell epitopes
  8. Micromirs
  9. METHODS FOR THE PRODUCTION OF IPS CELLS USING NON-VIRAL APPROACH
  10. HSA-RELATED COMPOSITIONS AND METHODS OF USE

Detail Information

Publications315 found, 100 shown here

  1. pmc The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species
    Bettina Gruhne
    Department of Cell and Molecular Biology, Karolinska Institutet, S 17177 Stockholm, Sweden
    Proc Natl Acad Sci U S A 106:2313-8. 2009
    ..These findings highlight a novel function of EBNA-1 and a possible mechanism by which expression of this viral protein could contribute to malignant transformation and tumor progression...
  2. doi The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC)
    Christopher W Dawson
    Birmingham Cancer Research UK Cancer Centre, School of Cancer Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom
    Semin Cancer Biol 22:144-53. 2012
    ..Here we review the effects of LMP1 and LMP2 on various aspects of epithelial cell behaviour highlighting key aspects that may contribute to the pathogenesis of NPC...
  3. pmc PRA1 promotes the intracellular trafficking and NF-kappaB signaling of EBV latent membrane protein 1
    Hao Ping Liu
    Institute of Microbiology and Immunology, National Yang Ming University, Shih Pai, Taipei, Taiwan, Republic of China
    EMBO J 25:4120-30. 2006
    ..These novel findings provide important new insights into LMP1, and identify an unexpected new role for PRA1 in cellular signaling...
  4. pmc Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines
    Lenka Skalska
    Section of Virology, Department of Medicine, Imperial College London, St Mary s Campus, London, United Kingdom
    PLoS Pathog 9:e1003187. 2013
    ..If cells are p16(INK4a)-null, functional EBNA3C is dispensable for the outgrowth of LCLs...
  5. pmc An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link
    Gemma L Kelly
    Cancer Research UK Institute for Cancer Studies, The University of Birmingham, Edgbaston, Birmingham, United Kingdom
    PLoS Pathog 5:e1000341. 2009
    ....
  6. pmc Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes
    Liliana Terrin
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico IRCCS, National Cancer Institute, Via Franco Gallini 2, 33081 Aviano PN, Italy
    J Virol 82:10175-87. 2008
    ....
  7. pmc Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A
    Sizun Jiang
    Department of Medicine, Brigham and Women s Hospital, Program in Virology, Department of Microbiology and Immunobiology, and Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115
    Proc Natl Acad Sci U S A 111:421-6. 2014
    ..05). These data support a model in which EBNA3C binds strongly to BATF/IRF4/SPI1/RUNX3 sites to enhance transcription and recruits RBPJ/Sin3A- and REST/NRSF-repressive complexes to repress p14(ARF) and p16(INK4A) expression. ..
  8. pmc Role for G-quadruplex RNA binding by Epstein-Barr virus nuclear antigen 1 in DNA replication and metaphase chromosome attachment
    Julie Norseen
    The Wistar Institute, Philadelphia, PA 19104, USA
    J Virol 83:10336-46. 2009
    ..These findings suggest that the EBNA1 replication and maintenance function uses a common G-quadruplex binding capacity of LR1 and LR2, which may be targetable by small-molecule inhibitors...
  9. pmc Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency
    Amanda R Robinson
    Department of Oncology McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706, USA
    J Virol 85:8940-53. 2011
    ..These results suggest that Oct-1 acts as a positive regulator of EBV lytic gene expression and that this effect is at least partially mediated through its interaction with the viral protein BRLF1...
  10. pmc Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex
    Hisae Matsuura
    Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 107:22641-6. 2010
    ..Multiple regions of gH/gL, including its two extreme ends, are functionally important, consistent with the multiple roles of gH/gL in EBV entry...
  11. pmc EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5
    Abhik Saha
    Department of Microbiology and Abramson Comprehensive Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Virol 85:2079-88. 2011
    ..This report demonstrates a possible role for the candidate tumor suppressor ING genes in the biology of EBV-associated cancers...
  12. pmc Modulation of LMP1 protein expression by EBV-encoded microRNAs
    Angela Kwok Fung Lo
    Viral Oncology Program, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 104:16164-9. 2007
    ..The data provide insight into the discrepancy between LMP1 transcript and protein detection in NPC and highlight the role of the EBV miRNAs in regulating LMP1 downstream signaling to promote cancer development...
  13. pmc Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin
    Jie Lu
    Department of Microbiology and Tumor Virology Program, Abramson Comprehensive Cancer Center, School of Medicine, University of Pennsylvania, 202E Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
    Virology 410:64-75. 2011
    ..Here, we suggest that EBV encoded EBNA1 can contribute to the oncogenic process by up-regulating the apoptosis suppressor protein, survivin in EBV-associated B-lymphoma cells...
  14. pmc Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein
    Bharat G Bajaj
    Department of Microbiology and Tumor Virology Program, Abramson Comprehensive Cancer Center, University of Pennsylvania Medical School, 201E Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
    J Virol 82:4082-90. 2008
    ..The inclusion of c-Myc in the group of cellular targets modulated by this domain further accentuates the importance of these critical residues of EBNA3C in bypassing the cell cycle checkpoints...
  15. pmc Epstein-Barr virus LF2: an antagonist to type I interferon
    Liguo Wu
    Department of Microbiology and Molecular Genetics, Tumor Virology Division, New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts 01772, USA
    J Virol 83:1140-6. 2009
    ..This demonstrates a novel immune evasion mechanism of EBV LF2 in blocking cellular IRF7-mediated innate immunity...
  16. pmc EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail
    Bryan D Griffin
    Department of Medical Microbiology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
    J Immunol 190:1672-84. 2013
    ..Therefore, this study furthers our knowledge of the evolution of immunoevasive functions by the lymphocryptovirus genus of herpesviruses...
  17. pmc Epstein-Barr virus essential antigen EBNA3C attenuates H2AX expression
    Hem C Jha
    Department of Microbiology and Tumor Virology Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Virol 88:3776-88. 2014
    ....
  18. pmc Epstein-Barr virus BGLF4 kinase induces premature chromosome condensation through activation of condensin and topoisomerase II
    Chung Pei Lee
    Graduate Institute and Department of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan
    J Virol 81:5166-80. 2007
    ....
  19. doi Activation of the ERK signal transduction pathway by Epstein-Barr virus immediate-early protein Rta
    Yu Hsiu Lee
    Institute of Microbiology and Immunology, National Yang Ming University, 155 Linong Street Section 2, Taipei 112, Taiwan, ROC
    J Gen Virol 89:2437-46. 2008
    ..Activation of the ERK signal transduction pathway by Rta may be critical for the maintenance of the lytic state of EBV...
  20. pmc Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines
    Bo Zhao
    Department of Medicine and Microbiology and Molecular Genetics, Channing Laboratory, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 108:337-42. 2011
    ..EBNA3C also up-regulated MYC 1.3-fold and down-regulated CDKN2A exons 2 and 3, shared by p16 and p14, 1.4-fold, with false discovery rates < 5 × 10(-4)...
  21. pmc Epstein-Barr virus LMP1 modulates lipid raft microdomains and the vimentin cytoskeleton for signal transduction and transformation
    David G Meckes
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Virol 87:1301-11. 2013
    ..These findings indicate that LMP1 reorganizes membrane and cytoskeleton microdomains to modulate signal transduction...
  22. pmc Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) and LMP2A function cooperatively to promote carcinoma development in a mouse carcinogenesis model
    Kathy H Y Shair
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Virol 86:5352-65. 2012
    ..This study is the first to characterize the effects of LMP2 on tumor initiation and promotion and to identify an effect of the combined expression of LMP1 and LMP2 on the increase of carcinoma development...
  23. pmc Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection
    Nirojini Sivachandran
    Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
    J Virol 86:6146-58. 2012
    ..Our results provide the first function for EBNA1 in lytic infection and show that EBNA1 interactions with PML IV lead to a loss of PML nuclear bodies (NBs) that promotes lytic infection...
  24. pmc Transcription profiling of Epstein-Barr virus nuclear antigen (EBNA)-1 expressing cells suggests targeting of chromatin remodeling complexes
    Ramakrishna Sompallae
    Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 5:e12052. 2010
    ..The interaction network of the affected gene products suggests that EBNA-1 may promote a broad rearrangement of the cellular transcription landscape by altering the expression of key components of chromatin remodeling complexes...
  25. pmc TAK1 is a component of the Epstein-Barr virus LMP1 complex and is essential for activation of JNK but not of NF-kappaB
    Noriyuki Uemura
    Department of Molecular Biology, Graduate School of Science, Nagoya University, Nagoya 464 8602, Japan
    J Biol Chem 281:7863-72. 2006
    ..These results suggest that an LMP1-associated complex containing TRAF6, TAB2, and TAK1 plays an essential role in the activation of JNK. However, TAK1 is not an exclusive intermediate for NF-kappaB activation in LMP1 signaling...
  26. pmc Negative autoregulation of Epstein-Barr virus (EBV) replicative gene expression by EBV SM protein
    Dinesh Verma
    Department of Medicine, UF Shands Cancer Center, University of Florida, Gainesville, 32610, USA
    J Virol 83:8041-50. 2009
    ..These data indicate that feedback regulation of immediate-early and early genes occurs during the lytic cycle of EBV regulation...
  27. pmc Epstein-Barr Virus SM protein utilizes cellular splicing factor SRp20 to mediate alternative splicing
    Dinesh Verma
    Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    J Virol 84:11781-9. 2010
    ..These data suggest a model whereby SM, a viral protein, recruits and co-opts the function of cellular SRp20 in alternative splicing...
  28. pmc Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma
    Qing Li Kong
    State Key Laboratory of Oncology in South China, Sun Yat sen University Cancer Center, Guangzhou, People s Republic of China
    PLoS Pathog 6:e1000940. 2010
    ..Taken together, our data indicate that LMP2A induces EMT and stem-like cell self-renewal in NPC, suggesting a novel mechanism by which Epstein-Barr virus induces the initiation, metastasis and recurrence of NPC...
  29. ncbi The Epstein-Barr virus replication and transcription activator, Rta/BRLF1, induces cellular senescence in epithelial cells
    Yu Lian Chen
    National Institute of Cancer Research, National Health Research Institutes, No 35 Keyan Road, Zhunan Town, Miaoli County, Taiwan
    Cell Cycle 8:58-65. 2009
    ....
  30. pmc Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1
    Marc Kvansakul
    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    PLoS Pathog 6:e1001236. 2010
    ....
  31. pmc Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1
    Abhik Saha
    Department of Microbiology and Tumor Virology Program, Abramson Comprehensive Cancer Center, University of Pennsylvania Medical School, Philadelphia, Pennsylvania, United States of America
    PLoS Pathog 7:e1001275. 2011
    ..Based on these results, we propose that EBNA3C can stabilize as well as enhance the functional activity of Cyclin D1 thereby facilitating the G1-S transition in EBV transformed lymphoblastoid cell lines...
  32. ncbi The C-terminal activating region 2 of the Epstein-Barr virus-encoded latent membrane protein 1 activates NF-kappaB through TRAF6 and TAK1
    Liming Wu
    Department of Biochemistry, Hong Kong University of Science and Technology, Clearwater Bay, Kowloon, Hong Kong, China
    J Biol Chem 281:2162-9. 2006
    ..Thus, LMP1 utilizes two distinct pathways to activate NF-kappaB: a major one through CTAR2/TRAF6/TAK1/IKKbeta (canonical pathway) and a minor one through CTAR1/TRAF3/NIK/IKKalpha (noncanonical pathway)...
  33. pmc Epstein-Barr virus BGLF4 kinase suppresses the interferon regulatory factor 3 signaling pathway
    Jiin Tarng Wang
    Graduate Institute and Department of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan
    J Virol 83:1856-69. 2009
    ..The data presented here thus suggest a novel mechanism by which herpesviral protein kinases suppress host innate immune responses and facilitate virus replication...
  34. pmc Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival
    Christoph Mancao
    GSF National Research Center for Environment and Health Department of Gene Vectors, Munich, Germany
    Blood 110:3715-21. 2007
    ....
  35. doi Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation
    Danielle Horst
    Department of Medical Microbiology, Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
    J Immunol 182:2313-24. 2009
    ..In this way, EBV BNLF2a-mediated evasion from HLA class I-restricted T cell immunity contributes to creating a window for undetected virus production...
  36. pmc Translation of intronless RNAs is strongly stimulated by the Epstein-Barr virus mRNA export factor EB2
    Emiliano P Ricci
    INSERM U758, Unité de Virologie Humaine, Ecole Normale Superieure de Lyon, Lyon F 69007, France
    Nucleic Acids Res 37:4932-43. 2009
    ..Finally, testing of EB2 homolog proteins derived from EBV-related herpesviruses, shows that, even if they play similar roles within the replication cycle of their respective virus, their mechanisms of action are different...
  37. doi LMP1 expression is positively associated with metastasis of nasopharyngeal carcinoma: evidence from a meta-analysis
    Yi Zhao
    Department of Pathology, School of Basic Medicine, The Fourth Military Medical University, Xi an, Shanxi, China
    J Clin Pathol 65:41-5. 2012
    ..This study evaluates the association of LMP1 expression with metastasis in NPC...
  38. pmc Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2
    P Rosato
    Department of Experimental Medicine, Istituto Pasteur Fondazione Cenci Bolognetti, La Sapienza University, Rome, Italy
    Leukemia 26:2343-52. 2012
    ....
  39. ncbi EBV latent membrane protein 2A induces autoreactive B cell activation and TLR hypersensitivity
    Hongsheng Wang
    Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA
    J Immunol 177:2793-802. 2006
    ..These data further implicate TLRs in the etiology of SLE and suggest a mechanistic link between EBV infection and SLE...
  40. pmc Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways
    Jennifer E Cameron
    Tulane University Health Sciences Center, 1430 Tulane Ave, SL79, New Orleans, LA 70112, USA
    J Virol 82:1946-58. 2008
    ....
  41. pmc Epstein-Barr virus associated modulation of Wnt pathway is not dependent on latent membrane protein-1
    Natasha Webb
    Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Brisbane, Australia
    PLoS ONE 3:e3254. 2008
    ..Taken together these studies demonstrate that EBV-mediated activation of Wnt pathway is not dependent on the expression of LMP1...
  42. ncbi Detection of Epstein-Barr virus BGLF4 protein kinase in virus replication compartments and virus particles
    Jiin Tarng Wang
    Graduate Institute and Department of Microbiology, College of Medicine, National Taiwan University, No 1 1st Section Jen Ai Road, Taipei, Taiwan
    J Gen Virol 86:3215-25. 2005
    ..Finally, possible functional domains at the N terminus of BGLF4 were analysed and it was found that aa 1-26 of BGLF4 are dispensable for EA-D phosphorylation, whereas deletion of aa 27-70 reduced kinase activity...
  43. ncbi The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy
    D Y Lee
    McArdle Laboratory for Cancer Research, University of Wisconsin Madison, Madison, WI 53706, USA
    Oncogene 27:2833-42. 2008
    ..These results indicate that LMP1's induction of autophagy contributes to its own regulation and that of its host cell...
  44. pmc Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2
    Walter Lucchesi
    Department of Virology, Faculty of Medicine, Imperial College London, St Mary s Campus, Norfolk Place, London W2 1PG, United Kingdom
    J Virol 82:7456-66. 2008
    ..The results indicate that differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2 may be the basis for the much weaker B-cell transformation activity of type 2 Epstein-Barr virus strains compared to type 1 strains...
  45. pmc Functional interaction between Epstein-Barr virus replication protein Zta and host DNA damage response protein 53BP1
    Sarah G Bailey
    The School of Life Sciences, University of Sussex, Brighton, East Sussex BN1 9QG, United Kingdom
    J Virol 83:11116-22. 2009
    Epstein-Barr virus (EBV; human herpesvirus 4) poses major clinical problems worldwide...
  46. pmc Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells
    Eri Seto
    Department of Gene Vectors, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Munich, Germany
    PLoS Pathog 6:e1001063. 2010
    ..The phenotypes of viral miRNAs uncovered by this genetic analysis indicate that they contribute to EBV-associated cellular transformation rather than regulate viral genes of EBV's lytic phase...
  47. pmc Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter
    Carmilia Jiménez-Ramírez
    Department of Biochemistry, MS 340, 332 North Lauderdale Street, Memphis, TN 38105, USA
    J Virol 80:11200-8. 2006
    ..These results indicate that EBNA-3C directly activates the expression of LMP-1 and LMP-2B but is unlikely to significantly regulate EBNA expression via Cp under normal growth conditions...
  48. pmc Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1
    Ami Watanabe
    Department of Tumor Virology, Institute for Genetic Medicine, Hokkaido University, N15W7, Kita ku, Sapporo 060 0815, Japan
    J Virol 84:2893-901. 2010
    ..These results indicate that EBV is essential for the survival of P3HR-1 cells and that BHRF1 functions as a survival factor. Our finding implies a critical contribution of BHRF1 to the pathogenesis of Wp-restricted BLs...
  49. doi Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis
    Abhik Saha
    Presidency University, Department of Biotechnology, 86 1, College Street, Kolkata 700073, West Bengal, India
    Future Microbiol 8:323-52. 2013
    ....
  50. pmc Epstein-Barr virus BGLF4 kinase retards cellular S-phase progression and induces chromosomal abnormality
    Yu Hsin Chang
    Graduate Institute and Department of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan
    PLoS ONE 7:e39217. 2012
    ..Taken together, our study indicates that BGLF4 may directly or indirectly induce a DNA damage signal that eventually interferes with host DNA synthesis and delays S-phase progression...
  51. ncbi Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma
    E Anderton
    Department of Virology, Faculty of Medicine, Imperial College London, Norfolk Place, London, UK
    Oncogene 27:421-33. 2008
    ..Our results may also explain the selection pressure that gives rise to a subset of BL that retain expression of the EBNA3 proteins...
  52. ncbi The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus
    Helmut Kutz
    GSF National Research Center for Environment and Health, Department of Gene Vectors, Marchioninistrasse 25, D 81377 Munich, Germany
    Virology 371:246-56. 2008
    ..Our data support a critical role of the LMP1-induced JNK pathway for proliferation of LMP1-transformed cells and characterize JNK as a potential target for intervention against EBV-induced malignancies...
  53. doi Epstein-Barr virus protein kinase BGLF4 interacts with viral transactivator BZLF1 and regulates its transactivation activity
    Risa Asai
    Division of Viral Infection, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Minato ku, Tokyo 108 8639, Japan
    J Gen Virol 90:1575-81. 2009
    ..These results indicate that formation of a stable complex of BGLF4-BZLF1 enables downregulation of BZLF1 autoregulation activity and it appears that BGLF4 phosphorylation of BZLF1 may be involved in these processes...
  54. doi Endoplasmic reticulum stress triggers XBP-1-mediated up-regulation of an EBV oncoprotein in nasopharyngeal carcinoma
    Jenn Ren Hsiao
    Department of Otolaryngology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    Cancer Res 69:4461-7. 2009
    ..Therefore, this study not only provides a novel clue linking ER stress/UPR to EBV-associated NPC but also suggests that ER stress/UPR can promote virus-associated cancer in a unique way by driving expression of a viral oncogene...
  55. doi Characterization of Epstein-Barr virus BGLF4 kinase expression control at the transcriptional and translational levels
    Jiin Tarng Wang
    Department of Microbiology, National Taiwan University, Taipei, Taiwan, Republic of China
    J Gen Virol 91:2186-96. 2010
    ..These results suggested that different promoter usage and 5'UTR-mediated translation enhancement may ensure the proper expression of BGLF4 at various stages of virus replication...
  56. doi Roles of TRAF2 and TRAF3 in Epstein-Barr virus latent membrane protein 1-induced alternative NF-kappaB activation
    Yoon Jae Song
    Department of Life Science, Kyungwon University, Kyeonggi Do, Korea
    Virus Genes 41:174-80. 2010
    ..Taken together, LMP1 activates alternative NF-kappaB pathway through functional NIK and IKKalpha that is regulated by TRAF2 or TRAF3...
  57. doi EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection
    Michiel van Gent
    Department of Medical Microbiology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
    J Immunol 186:1694-702. 2011
    ..Reducing the levels of a pattern-recognition receptor capable of sensing the presence of EBV provides a mechanism by which the virus could obstruct host innate antiviral responses...
  58. pmc Investigation of the function of the putative self-association site of Epstein-Barr virus (EBV) glycoprotein 42 (gp42)
    Cynthia L Rowe
    Department of Microbiology and Immunology, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Virology 415:122-31. 2011
    ..Using purified gp42, gH/gL, and HLA, we found these proteins associate 1:1:1 by gel filtration suggesting that gp42 dimerization or multimerization does not occur or is a transient event undetectable by our methods...
  59. pmc Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of Epstein-Barr virus reveal potential roles for EBNA1 in metastasis and oxidative stress responses
    Jennifer Yinuo Cao
    Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
    J Virol 86:382-94. 2012
    ..In addition, EBNA1 depletion in EBV-positive cells decreased NOX2 and ROS. The results show multiple roles for EBNA1 in the oxidative stress response pathway and suggest mechanisms by which EBNA1 may promote NPC metastases...
  60. pmc The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells
    Zachary L Pratt
    Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin Madison, Madison, Wisconsin, USA
    J Virol 86:4380-93. 2012
    ..These findings illustrate how the carboxy-terminal domain of LMP1 supports survival of B cells in the presence of the deleterious effects of the complex regulation of this viral oncogene...
  61. pmc EBV-encoded LMP1 upregulates Igκ 3'enhancer activity and Igκ expression in nasopharyngeal cancer cells by activating the Ets-1 through ERKs signaling
    Haidan Liu
    Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China
    PLoS ONE 7:e32624. 2012
    ..Our studies provide evidence for a novel regulatory mechanism of kappa expression, by which virus-encoded proteins activate the kappa 3' enhancer through activating transcription factors in non-B epithelial cancer cells...
  62. pmc EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors
    Robert E White
    Section of Virology, Faculty of Medicine, Imperial College London, London, United Kingdom
    J Clin Invest 122:1487-502. 2012
    ..Screening EBV-positive DLBCL, HL, and BL human samples identified additional EBNA3B mutations. Thus, EBNA3B is a virus-encoded tumor suppressor whose inactivation promotes immune evasion and virus-driven lymphomagenesis...
  63. pmc Epstein-Barr virus protein EB2 stimulates cytoplasmic mRNA accumulation by counteracting the deleterious effects of SRp20 on viral mRNAs
    Franceline Juillard
    INSERM U758, Unité de Virologie Humaine, 69364 Lyon, France
    Nucleic Acids Res 40:6834-49. 2012
    ..Moreover, by using RNA-immunoprecipitation assays we found that EB2 enhances the association of SRp20 with the β-globin transcript suggesting that EB2 acts by stabilizing SRp20's labile interactions with the RNA...
  64. pmc Epstein-Barr virus BGLF4 kinase downregulates NF-κB transactivation through phosphorylation of coactivator UXT
    Ling Shih Chang
    Graduate Institute and Department of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan
    J Virol 86:12176-86. 2012
    ..Taking the data together, transcription involving UXT may also be important for EBV lytic protein expression, whereas BGLF4-mediated phosphorylation of UXT at Thr3 plays a critical role in promoting the lytic cycle...
  65. pmc Role of TAF4 in transcriptional activation by Rta of Epstein-Barr Virus
    Ya Chun Yang
    Department of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei, Taiwan
    PLoS ONE 8:e54075. 2013
    ..This investigation reveals how Rta interacts with TFIID to stimulate transcription...
  66. pmc Epstein-Barr virus deubiquitinase downregulates TRAF6-mediated NF-κB signaling during productive replication
    Shinichi Saito
    Division of Virology, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Virol 87:4060-70. 2013
    ....
  67. pmc LMP1-induced cell death may contribute to the emergency of its oncogenic property
    Guillaume Brocqueville
    CNRS UMR8161, Institut de Biologie de Lille, Institut Pasteur de Lille, IFR 142, Universite Lille Nord de France, Lille, France
    PLoS ONE 8:e60743. 2013
    ..This cytotoxic effect is quite intriguing for an oncogenic protein, and it is unclear whether both functional aspects of the protein are related or mutually exclusive...
  68. pmc Caspase-1 promotes Epstein-Barr virus replication by targeting the large tegument protein deneddylase to the nucleus of productively infected cells
    Stefano Gastaldello
    Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
    PLoS Pathog 9:e1003664. 2013
    ....
  69. doi Inhibition of tumor necrosis factor-induced phenotypes by short intracellular versions of latent membrane protein-1
    Papa Alioune Ndour
    CNRS UMR, Institut de Biologie de Lille, IFR, Universite Lille Nord de France, France
    Cell Signal 22:303-13. 2010
    ..These data demonstrate that LMP1 derived molecules can be used to design compounds with potential therapeutic roles in diseases due to TNF overactivation...
  70. pmc Canonical NF-kappaB activation is essential for Epstein-Barr virus latent membrane protein 1 TES2/CTAR2 gene regulation
    Benjamin E Gewurz
    Channing Laboratory, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    J Virol 85:6764-73. 2011
    ..001-fold and >2-fold changes. Thus, canonical NF-κB activation is critical for almost all LMP1 TES2 RNA effects in HEK-293 cells and a more significant therapeutic target than previously appreciated...
  71. pmc Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II Epstein-Barr virus-transformed T cells
    Papa Alioune Ndour
    CNRS UMR8161, Institut de Biologie de Lille, IFR 142, Universite Lille Nord de France, Lille, France
    J Virol 86:3934-43. 2012
    ..Finally, we prove that synthetic peptides display similar inhibitory effects in EBV-infected cells. DNs derived from LMP1 could be used to develop therapeutic approaches for malignant diseases associated with EBV...
  72. doi Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell Lymphoma, nasal type (ENKL): differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL
    Naoko Kanemitsu
    Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan
    Clin Cancer Res 18:2164-72. 2012
    ..To elucidate its pathogenetic role, we examined the expression profiles of EBV-encoded proteins, especially focusing on latent membrane protein 1 (LMP1)...
  73. pmc Genetic diversity of EBV-encoded LMP1 in the Swiss HIV Cohort Study and implication for NF-Κb activation
    Emilie Zuercher
    Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    PLoS ONE 7:e32168. 2012
    ....
  74. ncbi The nested open reading frame in the Epstein-Barr virus nuclear antigen-1 mRNA encodes a protein capable of inhibiting antigen presentation in cis
    Martine Ossevoort
    Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands
    Mol Immunol 44:3588-96. 2007
    ..Even though the physiological function of pGZr remains to be elucidated, the GZ-repeat protein may be valuable as inhibitor of presentation of antigenic peptides derived from transgenes in gene therapy...
  75. ncbi Sumoylation of Rta of Epstein-Barr virus is preferentially enhanced by PIASxbeta
    Shih Tung Liu
    Molecular Genetics Laboratory, Department of Microbiology and Immunology, Chang Gung University, 259, Wen Hua 1st Road, Kwei Shan, Taoyuan 333, Taiwan
    Virus Res 119:163-70. 2006
    ....
  76. pmc Epstein-Barr virus LF2 protein regulates viral replication by altering Rta subcellular localization
    Andreas M F Heilmann
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Virol 84:9920-31. 2010
    ..Our results support a model in which LF2 regulates EBV replication by binding to Rta and redistributing it out of the nucleus...
  77. doi Epstein-Barr virus Rta-mediated transactivation of p21 and 14-3-3σ arrests cells at the G1/S transition by reducing cyclin E/CDK2 activity
    Sheng Yen Huang
    Department of Microbiology, College of Medicine, National Taiwan University, Taipei 100, Taiwan, ROC
    J Gen Virol 93:139-49. 2012
    ..Based on these results, we hypothesize that through the disruption of CDK1 and CDK2 activities, EBV Rta might contribute to cell cycle arrest in EBV-infected epithelial cells during viral reactivation...
  78. pmc Epstein-Barr virus latent membrane protein 2A promotes invasion of nasopharyngeal carcinoma cells through ERK/Fra-1-mediated induction of matrix metalloproteinase 9
    Yu Yan Lan
    National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan
    J Virol 86:6656-67. 2012
    ....
  79. pmc EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells
    Francesco Boccellato
    Istituto Pasteur Fondazione Cenci Bolognetti, Department of Experimental Medicine and Pathology, University of Rome La Sapienza, Viale Regina Elena 324, 00161 Rome, Italy
    J Virol 81:2274-82. 2007
    ..These findings suggest that EBNA2 interferes with the GC phenotype...
  80. pmc Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22
    Raymond Wai Ming Lung
    Department of Anatomical and Cellular Pathology at Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China
    Neoplasia 11:1174-84. 2009
    ..Our findings emphasize the role of miR-BART22 in modulating LMP2A expression, which may facilitate NPC carcinogenesis by evading the host immune response...
  81. doi Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A
    Rumi Hino
    Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Cancer Res 68:1427-35. 2008
    ....
  82. pmc LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells
    Haidan Liu
    Cancer Research Institute, Xiangya School of Medicine, Central South University, Xiangya Road 110, Changsha, Hunan 410078, PR China
    Mol Cancer 8:92. 2009
    ....
  83. pmc CKII site in Epstein-Barr virus nuclear protein 2 controls binding to hSNF5/Ini1 and is important for growth transformation
    Bogaslaw Kwiatkowski
    VA Puget Sound Health Care System, S 111 ONC, 1660 S Columbian Way, Seattle, WA 98108, USA
    J Virol 78:6067-72. 2004
    ..An alanine substitution (SS469AA) prevents binding to EBNA2 and diminishes the growth-promotion potential of EBNA2 in the transcomplementation assay...
  84. ncbi Structural features of the single-stranded DNA-binding protein of Epstein-Barr virus
    E Mumtsidu
    European Molecular Biology Laboratory, Hamburg Outstation, Notkestrasse 85, D 22603 Hamburg, Germany
    J Struct Biol 161:172-87. 2008
    ..One major difference is the tendency of Balf2DeltaC to dimerize on different surfaces to that used for oligomerization when binding to ssDNA, and this may have implications for the mechanism of replication initiation...
  85. pmc Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo
    Leah J Anderson
    Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, 303 E Chicago Avenue, Chicago, IL 60611, USA
    Blood 113:108-16. 2009
    ..Interestingly, Notch1 appears to be important for LMP2A-mediated survival in low interleukin-7. We propose that LMP2A and the Notch1 pathway may cooperate to induce the alterations in B-cell identity seen in Hodgkin Reed-Sternberg cells...
  86. pmc Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta
    Che Pei Kung
    Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Virol 85:4399-408. 2011
    ..These findings indicate that LMP1 activates multiple distinct signaling pathways and suggest that PKCδ functions as a master regulator of EGFR, STAT3, and ERK activation by LMP1-CTAR1...
  87. ncbi Epstein-Barr virus nuclear antigen 2 induces FcRH5 expression through CBF1
    Joanne Mohan
    Division of Monoclonal Antibodies, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    Blood 107:4433-9. 2006
    ..These results identify FcRH5 as a novel, direct target of EBNA2 that may contribute to the development of Epstein-Barr virus-associated tumors...
  88. pmc Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma
    Yanjun Jiang
    Nebraska Center for Virology, University of Nebraska, Lincoln, Nebraska, USA
    PLoS ONE 3:e1569. 2008
    ..KSHV replication and transcription activator (K-RTA) is necessary and sufficient for the switch from KSHV latency to lytic replication, while EBV BZLF1 gene product (EBV-Z) is a critical initiator for induction of EBV lytic replication...
  89. pmc STAP-2 negatively regulates both canonical and noncanonical NF-kappaB activation induced by Epstein-Barr virus-derived latent membrane protein 1
    Osamu Ikeda
    Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060 0812, Japan
    Mol Cell Biol 28:5027-42. 2008
    ..Finally, STAP-2 knockout mouse embryonic fibroblasts showed enhanced LMP1-induced cell growth. These results suggest that STAP-2 acts as an endogenous negative regulator of EBV LMP1-mediated signaling through TRAF3 and TRADD...
  90. doi Latent membrane protein-1 of Epstein-Barr virus induces the expression of B-cell integration cluster, a precursor form of microRNA-155, in B lymphoma cell lines
    Nur Rahadiani
    Department of Pathology, Osaka University Graduate School of Medicine, 2 2Yamadoka, Suita, Osaka 565 0871, Japan
    Biochem Biophys Res Commun 377:579-83. 2008
    ..These results suggest that BIC/miR-155 play a role in lymphomagenesis through NF-kappaB and p38/MAPK pathways in response to activation by EBV LMP1...
  91. doi Epstein-Barr virus-derived EBNA2 regulates STAT3 activation
    Ryuta Muromoto
    Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita Ku Kita 12 Nishi 6, Sapporo 060 0812, Japan
    Biochem Biophys Res Commun 378:439-43. 2009
    ..Furthermore, EBNA2 cooperatively acts on STAT3 activation with LMP1. These data demonstrate that EBNA2 acts as a transcriptional coactivator of STAT3...
  92. pmc Interaction of Epstein-Barr virus BZLF1 C-terminal tail structure and core zipper is required for DNA replication but not for promoter transactivation
    Carol M McDonald
    Department of Virology, Imperial College London, Norfolk Place, London W2 1PG, United Kingdom
    J Virol 83:3397-401. 2009
    ....
  93. pmc Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta
    Gretchen L Bentz
    Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, NC, USA
    Virology 402:121-8. 2010
    ..These data suggest a new role for BRLF1 with the ability to evade host innate immune responses...
  94. pmc Evidence for DNA hairpin recognition by Zta at the Epstein-Barr virus origin of lytic replication
    Andrew J Rennekamp
    The Wistar Institute, 3601 Spruce St, Philadelphia, PA 19104, USA
    J Virol 84:7073-82. 2010
    ....
  95. ncbi Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells
    Robert Touitou
    Department of Virology and Ludwig Institute for Cancer Research, Wright Fleming Institute, Faculty of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK
    J Gen Virol 86:1269-77. 2005
    ..In actively proliferating lymphoblastoid cell lines, EBNAs 3A, 3B and 3C appear to be remarkably stable, with no evidence of either de novo synthesis or proteasome-mediated degradation...
  96. pmc EBNA1 regulates cellular gene expression by binding cellular promoters
    Allon Canaan
    Department of Genetics, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 106:22421-6. 2009
    ..We have correlated EBNA1 bound promoters with changes in gene expression. Sequence analysis of the 100 promoters most enriched revealed a DNA motif that differs from the EBNA1 binding site in the EBV genome...
  97. pmc The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block
    Tathagata Choudhuri
    Department of Microbiology and the Tumor Virology Program, Abramson Comprehensive Cancer Center, University of Pennsylvania School of Medicine, 201E Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
    J Virol 81:6718-30. 2007
    ..Overall, our data suggest that EBNA3C can directly regulate the G2/M component of the host cell cycle machinery, allowing for the release of the checkpoint block...
  98. pmc Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5
    Stephanie Barth
    Institute of Virology, University of Saarland Medical School, 66424 Homburg, Germany
    Nucleic Acids Res 36:666-75. 2008
    ..Our results are compatible with the notion that EBV-miR-BART2 inhibits transition from latent to lytic viral replication...
  99. doi Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b
    E Anastasiadou
    Department of Experimental Medicine and Pathology, Istituto Pasteur Fondazione Cenci Bolognetti, La Sapienza University, Rome, Italy
    Oncogene 29:1316-28. 2010
    ....
  100. pmc Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase
    Jason S Knight
    Department of Microbiology and the Tumor Virology Program, Abramson Comprehensive Cancer Center, University of Pennsylvania, 201E Johnson Pavilion, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 102:18562-6. 2005
    ..That EBNA3C has exploited this association suggests that other human malignancies might use a similar strategy to regulate the Rb protein...
  101. pmc Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1)
    Fang Lu
    The Wistar Institute, Philadelphia, PA 19104, USA
    Virol J 7:262. 2010
    ..We conclude that EBNA1 can interact with a large number of cellular genes and chromosomal loci in latently infected cells, but that these sites are likely to represent a complex ensemble of direct and indirect EBNA1 binding sites...

Research Grants73

  1. Ren Sun; Fiscal Year: 2016
    ..Moreover, elucidating the anti-IFN function of a group of conserved viral proteins may reveal potential targets for therapeutic measures. ..
  2. Chronic High EBV load and risk of PTLD in Pediatric Heart Transplant Patients
    Diana M Metes; Fiscal Year: 2013
    ..disorders (PTLD) are life-threatening complications of solid organ transplantation (SOTx), caused by Epstein Barr Virus (EBV) infections and the use of chronic non-specific immunosuppression (IS)...
  3. T Cell Immunity in Endemic Burkitt Lymphoma
    Ann M Moormann; Fiscal Year: 2012
    ..Results from this research will ultimately improve the prospects for successful cancer immunotherapies and vaccine development for EBV-associated lymphomas such as BL. ..
  4. EBNA1 Functions Required in Burkitt's Lymphomas and Other Immortalized B-Cells
    AMBER TERESA WASHINGTON; Fiscal Year: 2012
    ..My studies will identify new therapeutic targets against diseases and malignancies caused by latent EBV infections. ..
  5. Anti-viral DC/NK interactions
    CHRISTIAN MUNZ; Fiscal Year: 2012
    ..Our preliminary data demonstrate that NK cell activation by DCs restricts B cell transformation by the Epstein Barr virus (EBV) in vitro, especially when the NK cells are derived from tonsils, the secondary lymphoid organ of ..
  6. THE ROLE OF EPSTEIN-BARR VIRUS EBNA1, LMP1 AND LMP2A PRO
    Richard Longnecker; Fiscal Year: 2003
    ..Understanding the role of EBNA1, LMP1, and, LMP2A in NPC may suggest novel therapeutics for the treatment of NPC, and a better understanding of factors that can influence the development of oral cancers. ..
  7. PREVENTION AND ANTIVIRAL TREATMENT FOR EBV LYMPHOMAGENESIS
    Joseph S Pagano; Fiscal Year: 2013
    ..Results may also be of use in patients with AIDS who have rising EBV viral loads that may herald genesis of B-cell lymphomas. ..
  8. Regulation of EBV Latency by Chromosome Conformation
    Italo Tempera; Fiscal Year: 2012
    ..This work will facilitate the treatment of EBV-related malignancies. ..
  9. Elliott D Kieff; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Epstein Barr Virus (EBV) is a prominent cause of African Burkitt's Lymphoma, Hodgkin's Lymphomas, malignant Lymphoproliferative Diseases in immune suppressed and HIV infected people, ..
  10. EBNA3C and tumor supressors
    Erle S Robertson; Fiscal Year: 2010
    ..abstract_text> ..
  11. RICHARD M LONGNECKER; Fiscal Year: 2016
    ....
  12. Paul M Lieberman; Fiscal Year: 2016
    ..The proposed studies should further our understanding of EBV latent cycle gene regulation and host-virus interactions. ..
  13. Assay Development for Inhibitors of KSHV
    Paul M Lieberman; Fiscal Year: 2010
    ..Finally, this research may provide therapeutic strategies for related tumor viruses, especially EBV and human papillomavirus (HPV), which possess LANA-like orthologues. ..
  14. Virus-Targeted Therapy for Malignancies
    SUSAN PARK PERRINE; Fiscal Year: 2011
    ..We propose here to identify a more potent and optimized inducing agent and antiviral agent, and demonstrate their anti-tumor activity in an animal model. ..
  15. MOLECULAR BIOLOGY OF EPSTEIN-BARR VIRUS INFECTION
    Elliott Kieff; Fiscal Year: 2000
    ..Since the effects of EBV on B lymphocytes closely parallel those of antigen stimulation, these studies are expected to increasingly intersect with and contribute to pathways of antigen driven B lymphocyte proliferation. ..
  16. Carlos O Esquivel; Fiscal Year: 2016
    ..Our goal is the development of a biomarker that would identify patients at risk for PTLD or those in the very early stages of the disease, which will represent a major advance in pediatric solid organ transplantation. ..
  17. Claudio Anasetti; Fiscal Year: 2016
    ..The number of patients cured from blood disorders will increase. The Moffitt Cancer Center will contribute to the conception of multicenter clinical trials, patient enrollment, data analysis and knowledge dissemination. ..
  18. HUMAN B CELL TRANSFORMATION BY EPSTEIN BARR VIRUS
    Jennifer Martin; Fiscal Year: 1999
    ....
  19. Paul M Lieberman; Fiscal Year: 2016
    ..More detailed understanding of EBNA1 is further justified by its potential value as a target for therapeutic intervention in diseases and cancers associated with EBV latent infection. ..
  20. SPORE in Lymphoma
    Richard Ambinder; Fiscal Year: 2009
    ..abstract_text> ..
  21. Varicella-Zoster Virus Encapsidation Proteins
    Robert J Visalli; Fiscal Year: 2010
    ..Our laboratory focuses on understanding new strategies to inhibit herpesvirus replication, namely, on a series of novel drug candidates that prevent infectious viral particles from forming in infected cells. ..
  22. Epstein-Barr Virus-Enhanced Tumor Progression
    Rona S Scott; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Among human viruses etiologically linked to human cancer, the Epstein Barr virus (EBV) is unusual because of the diverse assortment of malignancies with which it is associated, if only sporadically...
  23. Herpesvirus protein kinases: Substrate recognition and pathway targeting.
    S Diane Hayward; Fiscal Year: 2013
    ..b>Epstein Barr Virus (EBV) and Kaposi's sarcoma associated herpesvirus (KSHV) are associated with AIDS related cancers and ..
  24. The role of CD8+ T cells in response to EBV-induced infectious mononucleosis
    Oludare A Odumade; Fiscal Year: 2010
    ..Exposure to Epstein Barr virus, a y-herpesvirus, during the first decade of life rarely results in clinical symptoms...
  25. Transport and Insertion of Outer Membrane Proteins
    Sangita Sinha; Fiscal Year: 2009
    ..This application aims to investigate atomic details of the mechanism by which 3-herpesviruses inhibit autophagy, providing a better understanding of 3-herpesviral pathogenicity. ..
  26. Mechanisms of Fatigue in a Chronic Viral Disease
    Linda A Toth; Fiscal Year: 2012
    ..Such a long-term result would improve the quality of life and economic welfare of target populations that span many disease conditions. ..
  27. Mechanisms of Gene Regulation by EBV EBNA-1 Protein
    Jeffery T Sample; Fiscal Year: 2010
    ....
  28. Rapid FISH Detection of EBV-infected Cells
    RAYMOND PRESTON STOWE; Fiscal Year: 2010
    ..We will develop a novel FISH-based assay to detect EBV-infected cells in peripheral blood at the single-cell level which can be used to better understand the immunology of EBV in aging. ..
  29. Impact of herpesvirus protein kinases on host protein modification
    Renfeng Li; Fiscal Year: 2013
    ..I propose a novel strategy using high throughput mass spectrometry to dissect the complex signaling networks regulated by BGLF4. ..
  30. Inhibitors of Epstein-Barr Virus Nuclear Protein 1 Mediated Latent Infection
    Elliott D Kieff; Fiscal Year: 2013
    ..4) Use reverse genetics to identify the critical residues in EBNA1 DBD that can improve screening sensitivity and inform in silico pocket selection, compound modification, and compound interaction analyses. ..
  31. Regulation of replication and latency EBV EBNAs
    S Diane Hayward; Fiscal Year: 2012
    ..abstract_text> ..
  32. Sankar Swaminathan; Fiscal Year: 2015
    ..This proposal is to study how EBV manipulates the infected cell to avoid the immune response (host defenses) and enhance its own replication. ..
  33. John C Cambier; Fiscal Year: 2014
    ..In what is perhaps the best example of this association, Epstein Barr Virus infection appears to predispose to development of Systemic Lupus Erythematosus...
  34. FREDERICK C WANG; Fiscal Year: 2014
    ....
  35. Mechanisms of Epstein-Barr Virus Persistence
    Jeffery T Sample; Fiscal Year: 2013
    ..Finally, in Aim 3 we will characterize and explore the contribution to EBV latency of a family of novel RNA transcripts that span the EBNA promoter Cp. ..
  36. BENJAMIN ELISON GEWURZ; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): The Epstein Barr Virus (EBV) is an oncogenic gamma-herpesvirus that is associated with Hodgkin disease and anaplasmic nasopharyngeal carcinoma...
  37. EBV Antigen and Cell Cycle Regulation
    Erle S Robertson; Fiscal Year: 2013
    ..Simultaneously, we will generate site specific recombinant EBNA3C molecules that are knocked out for the specific interactions within the EBV genome to determine their role in primary B cell transformation. ..
  38. Inhibition of mTOR Alters Epstein-Barr Virus Lytic Replication
    Amy L Adamson; Fiscal Year: 2012
    ..The goals of this study are aimed at assessing the abilityof mTOR inhibitors to prevent EBV lytic replication in different cell types, as well as determining the mechanism by which these inhibitors inhibit EBV lytic replication. ..
  39. Elliott D Kieff; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Epstein Barr Virus (EBV) is causally related to Burkitt's Lymphoma, Hodgkin's Lymphoma, and Lymphoproliferative Diseases in immune suppressed and HIV infected people...
  40. Joint Mapping of Genome-Wide Gene Expression and Association in a Schizophrenia D
    Alan R Sanders; Fiscal Year: 2010
    ..genome-wide gene expression levels utilizing the Illumina HT-12 array in a well-powered sample comprised of Epstein Barr Virus (EBV) transformed B lymphocytes (lymphoblastoid cell lines, LCLs) from 1,011 severely affected cases and 1,..
  41. Light Weight Modeling of Epstein Barr Virus
    Michael D Shapiro; Fiscal Year: 2012
    ..Computer simulation is a way to study the normal asymptomatic course of this infection and the ways in which this turns malignant. We hope that a better understanding of these processes will show us how they can be controlled. ..
  42. Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
    RICHARD M LONGNECKER; Fiscal Year: 2012
    ..Our specific goals are to identify drugs that target EBV latent infections and EBV-associated lymphomas that occur in the human host by using inhibitors of cell proteins targeted by EBV. ..
  43. Probing EBV-LMP-1's Transmembrane Activation Domain with Synthetic Peptide Antago
    HANG contact YIN; Fiscal Year: 2010
    ..specifically and with affinity to LMP-1's TMD-1 in vitro? and 3) Can peptides that target TMD-1 (identified in Aims 1 and 2) interfere with LMP-1 homo-oligomerization, raft association, and constitutive signaling in intact cells? ..
  44. PAUL DALLING LING; Fiscal Year: 2014
    ..Our studies will yield new insights into virus-host interactions that modulate viral infections and possibly identify new viral targets for development of novel antiviral therapeutics. ..
  45. HANG HUBERT YIN; Fiscal Year: 2016
    ..Specifically, this proposal addresses the following Aims: 1) Develop specific peptide probes targeting individual TMDs of LMP-1;and 2) Determine the role of TMD-mediated oligomerization in LMP-1 activation. ..
  46. Novel Carrier for Polysaccharide Conjugates and an EBV Vaccine
    CLIFFORD SNAPPER; Fiscal Year: 2009
    ....
  47. Eleanor M Riley; Fiscal Year: 2016
    ..phenotype and function;iii) Screen samples for evidence of herpesvirus infection and viral load, focusing on Epstein Barr virus (EBV), cytomegalovirus (CMV), and human herpesvirus-6 (HHV-6);iv) Describe clinical phenotype and ..
  48. Italo Tempera; Fiscal Year: 2014
    ..The goal of this project is to improve our understanding of the molecular mechanism that regulates EBV latency types. ..
  49. The Structural basis of EBV Attachment: CD21 & gp350/220
    Joyce Fingeroth; Fiscal Year: 2005
    ..abstract_text> ..
  50. Detection and CTL Therapy of PTLD After Liver Transplant
    John Goss; Fiscal Year: 2004
    ..The data from our proposed study will provide the database for the development of future larger multi-centered trials to determine the utility of this adoptive immunotherapeutic regimen ..
  51. Bryan R Cullen; Fiscal Year: 2016
    ....
  52. EPSTEIN BARR VIRUS INDUCED GENOMIC INSTABILITY
    John Sixbey; Fiscal Year: 2005
    ....
  53. Scott A Tibbetts; Fiscal Year: 2014
    ..This work has important implications for the development of drugs to prevent or treat virus-associated cancers. ..
  54. Chimeric T Cell for Therpay of Hodgkin Disease
    Barbara Savoldo; Fiscal Year: 2012
    ..We now want to extend the application of this promising treatment by targeting other proteins that are on all HD cells, and by making the immune cells more potent. ..
  55. RELIABILITY OF EBV DETECTION IN HODGKINS DISEASE TUMORS
    Sally Glaser; Fiscal Year: 1999
    ....
  56. CD23--AUTOCRINE GROWTH FACTOR AND RECEPTOR
    Wayne Marasco; Fiscal Year: 1991
    ..Lastly, mutant CD23 molecules will be constructed in order to delineate the mechanism of receptor shedding and to determine the active domain(s) involved in cell binding and cell activation...
  57. EPIDEMIOLOGY OF EBV DEFINED HODGKINS DISEASE
    Sally Glaser; Fiscal Year: 1999
    ....
  58. Function of the Epstein-Barr Virus EBNA-A3 Protein
    Clare E Sample; Fiscal Year: 2010
    ....
  59. Modulation of histone deacetylase activity by a gammaherpesviral kinase
    Bryan C Mounce; Fiscal Year: 2013
    ..Several orf36 functions are conserved in other gammaherpesviral kinases;thus, the results of our studies are expected to translate to human pathogens. ..
  60. Edward H Egelman; Fiscal Year: 2016
    ..Herpes Simplex Type 1 Virus (HSV-1) ICP8, but will then be extended to related viral proteins, such as from Epstein Barr Virus and Kaposi Sarcoma Herpes Virus...
  61. CELLULAR MECHANISMS OF PTLD IN TRANSPLANT RECIPIENTS
    Olivia M Martinez; Fiscal Year: 2012
    ..The hallmark of PTLD is the development of Epstein Barr Virus (EBV)-associated B cell lymphomas...
  62. E3 Ubiquitin Ligase Functions in Enveloped Virus Budding
    ANDREW PAUL NORGAN; Fiscal Year: 2012
    ..The insights gained from this research will have broad application to the study of other enveloped viruses, including Epstein- Barr virus. Human T-cell Lymophotropic virus. Influenza virus, and others. ..
  63. Herpesvirus-induced telomerase dysregulation and tumor formation
    Keith William Jarosinski; Fiscal Year: 2011
    ..It will also address the mechanism of herpesvirus integration into the host genome and its importance for latent infection and transformation of lymphocytes. ..
  64. Richard J Samulski; Fiscal Year: 2014
    ....
  65. CSHL Eukaryotic DNA Replication Conference
    David J Stewart; Fiscal Year: 2013
    ....
  66. Bert L Semler; Fiscal Year: 2016
    ....
  67. Development of a novel vaccine for protection against gammaherpesvirus infection
    Blossom A Damania; Fiscal Year: 2010
    ..Thus, this collaborative project integrates the PI's expertise in KSHV and RRV, with Dr. Desrosiers'expertise in vaccine design and development, and the use of primate infection models for RRV. ..
  68. Identification of Genetic Modifiers of an Epstein-Barr Virus Protein.
    AMY ADAMSON; Fiscal Year: 2007
    ..Our studies aim to find human genes whose protein products enhance or suppress Epstein-Barr virus protein activity. [unreadable] [unreadable] [unreadable]..
  69. Inducing and targeting of EBV lytic antigens in lymphoma
    Sven de Vos; Fiscal Year: 2006
    ..We anticipate a successful clinical trial and plan the extension to a larger multi center clinical trial in the time following the K23 granting period. ..
  70. EBV-Specific T-Cell Therapy for Nasopharynx Cancer: Immunomodulation and Response
    Marshall Posner; Fiscal Year: 2009
    ..This creates a cellular anti-cancer vaccine that can be given back to the same patient and treat the cancer. We plan to study this process and see if we can improve the effectiveness of the therapy. ..
  71. Development of Vaccine Strategies to prevent EBV+ Lymphoma in Patients with HIV
    ROBERT ALAN BAIOCCHI; Fiscal Year: 2010
    ..The project has great potential to make an impact on public health, job creation and economic growth. ..
  72. THERAPY FOR AIDS CENTRAL NERVOUS SYSTEM LYMPHOMA
    Michael Caligiuri; Fiscal Year: 2002
    ..The limitations of the animal model preclude its use for studying the pathogenesis of AIDS PCNSL. ..
  73. Assay For Inhibitors of Epstein-Barr Virus
    Paul Lieberman; Fiscal Year: 2009
    ....

Patents62

  1. Methods for the production of iPS cells using non-viral approach
    Patent Number: KR1020160025045-A; Date:2016-03-07
  2. Method of detection and quantitation of a target nucleic acid in a test sample utilizing a novel positive control nucleic acid
    Patent Number: WO2016059798-A; Date:2016-04-21
  3. Novel Nucleic Acid Molecules
    Patent Number: JP2016509855-A; Date:2016-04-04
  4. HUMAN HERPESVIRUS TRIMERIC GLYCOPROTEIN B, PROTEIN COMPLEXES COMPRISING TRIMERIC GB AND THEIR USE AS VACCINES
    Patent Number: EP3079718-A1; Date:2016-10-19
  5. BIOMARKERS FOR ENDOMETRIOSIS
    Patent Number: WO2015128671-A1; Date:2015-09-03
  6. MULTIMERIC FUSION PROTEIN VACCINE AND IMMUNOTHERAPEUTIC
    Patent Number: JP2015530369-A; Date:2015-10-15
  7. B-cell receptor complex binding proteins containing T-cell epitopes
    Patent Number: JP2015516376-A; Date:2015-06-11
  8. Micromirs
    Patent Number: JP2015130862-A; Date:2015-07-23
  9. METHODS FOR THE PRODUCTION OF IPS CELLS USING NON-VIRAL APPROACH
    Patent Number: JP2014209912-A; Date:2014-11-13
  10. HSA-RELATED COMPOSITIONS AND METHODS OF USE
    Patent Number: KR1020140012094-A; Date:2014-01-29
  11. HSA-Related Compositions and Methods of Use
    Patent Number: JP2014510518-A; Date:2014-05-01
  12. EPSTEIN-BARR VIRUS VACCINES
    Patent Number: WO2015054639-A1; Date:2015-04-16
  13. NOVEL NUCLEIC ACID MOLECULES
    Patent Number: KR1020150128892-A; Date:2015-11-18
  14. MODIFIED EPSTEIN-BARR VIRUS DNA POLYMERASE AND METHODS FOR ISOTHERMAL DNA AMPLIFICATION
    Patent Number: WO2015031206-A1; Date:2015-03-05
  15. HSA-RELATED COMPOSITIONS AND METHODS OF USE
    Patent Number: EP2675471-A1; Date:2013-12-25
  16. Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
    Patent Number: WO2007047859-A2; Date:2007-04-26
  17. HSA-RELATED COMPOSITIONS AND METHODS OF USE
    Patent Number: EP2536756-A1; Date:2012-12-26
  18. Rationally designed meganucleases with altered sequence specifity and DNA-binding affinity
    Patent Number: EP2650366-A2; Date:2013-10-16
  19. B-CELL RECEPTOR COMPLEX BINDING PROTEINS CONTAINING T-CELL EPITOPES
    Patent Number: WO2013139789-A1; Date:2013-09-26
  20. Peptides and nucleic acid sequences related to Epstein Barr virus
    Patent Number: EP1225226-A1; Date:2002-07-24
  21. Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells
    Patent Number: WO02090533-A2; Date:2002-11-14
  22. Oligonucleotides for the amplification and detection of epstein barr virus (ebv) nucleic acid
    Patent Number: WO9945155-A2; Date:1999-09-10
  23. Quantitative epstein barr virus pcr rapid assay
    Patent Number: WO02064842-A2; Date:2002-08-22
  24. Detection and quantification of human herpes viruses
    Patent Number: WO0234953-A2; Date:2002-05-02
  25. Novel expression vectors and uses thereof
    Patent Number: JP2004533247-A; Date:2004-11-04
  26. ANTIBODY TO LATENT MEMBRANE PROTEINS AND USES THEREOF
    Patent Number: JP2005511047-A; Date:2005-04-28
  27. Mutant type EBNA1
    Patent Number: JP2006121995-A; Date:2006-05-18
  28. HSA-RELATED COMPOSITIONS AND METHODS OF USE
    Patent Number: KR1020130020765-A; Date:2013-02-28
  29. Epstein-Barr virus-Specific Cytotoxic T Lymphocyte Epitope Peptides And The Uses Thereof
    Patent Number: JP2007117023-A; Date:2007-05-17
  30. Epstein-Barr virus-Specific Cytotoxic T Lymphocyte Epitope Peptides And The Uses Thereof
    Patent Number: WO2007049737-A; Date:2007-05-03
  31. Peptides and Nucleic Acid Sequences Related to the Epstein Barr
    Patent Number: JP2008261851-A; Date:2008-10-30
  32. Methods and kits for detecting and identifying virus-infected cells
    Patent Number: WO2009116266-A; Date:2009-09-24
  33. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
    Patent Number: WO2006105361-A; Date:2006-10-05
  34. METHODS FOR AMPLIFICATION OF GENOME AND MIXTURES OF INITIATOR OLIGONUCLEOTIDES FOR THE DETECTION AND IDENTIFICATION OF RELATED GENOMIC SEQUENCES
    Patent Number: WO9325707-A2; Date:1993-12-23
  35. Viral and viral associated mirnas and uses thereof
    Patent Number: WO2005116250-A2; Date:2005-12-08
  36. Reagents and method for simultaneous nucleic acid amplification and detection
    Patent Number: WO2007060707-A2; Date:2007-05-31
  37. Novel disease treatments
    Patent Number: WO2008125366-A1; Date:2008-10-23
  38. Micromirs
    Patent Number: WO2009043353-A1; Date:2009-04-09
  39. Amplification capture assay
    Patent Number: JP2000325093-A; Date:2000-11-28
  40. NON-SPLICING VARIANTS OF gp 350/220
    Patent Number: JP2003230396-A; Date:2003-08-19
  41. Analysis of nucleic acids
    Patent Number: WO2009130480-A1; Date:2009-10-29
  42. Methods for the production of ips cells using non-viral approach
    Patent Number: WO2009149233-A1; Date:2009-12-10
  43. Anti-gd2 antibodies and methods and uses related thereto
    Patent Number: WO2010002822-A1; Date:2010-01-07
  44. Leukocyte expression profiling
    Patent Number: EP1334113-A2; Date:2003-08-13
  45. Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome
    Patent Number: EP2215252-A2; Date:2010-08-11
  46. Method for the identification of antigens expressed in vivo, diagnostic assays therefor and vaccines containing them
    Patent Number: EP0316170-A2; Date:1989-05-17
  47. Epstein-Barr virus DNA sequences encoding a diagnostically relevant virus capsid antigen, expression clones derived through polymerase chain reaction and the use of this recombinant antigen in diagnostic tests
    Patent Number: EP0726315-A1; Date:1996-08-14
  48. PEPTIDES AND NUCLEIC ACID SEQUENCES RELATED TO EPSTEIN BARR VIRUS
    Patent Number: EP0574048-A2; Date:1993-12-15
  49. Novel expression vectors and uses thereof
    Patent Number: JP2010042000-A; Date:2010-02-25
  50. RATIONALLY-DESIGNED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN DNASE HYPERSENSITIVE REGIONS OF THE HUMAN GENOME
    Patent Number: JP2011505809-A; Date:2011-03-03
  51. FUSION MOLECULES OF RATIONALLY-DESIGNED DNA-BINDING PROTEINS AND EFFECTOR DOMAINS
    Patent Number: JP2011519558-A; Date:2011-07-14
  52. EBNA1 function inhibitor
    Patent Number: WO2011115246-A; Date:2011-09-22
  53. METHODS FOR THE PRODUCTION OF IPS CELLS USING NON-VIRAL APPROACH
    Patent Number: JP2011522540-A; Date:2011-08-04
  54. EBNA1 function inhibitor
    Patent Number: JP2011213704-A; Date:2011-10-27
  55. RESEQUENCING PATHOGEN MICROARRAY
    Patent Number: JP2011204261-A; Date:2011-10-13
  56. ANTI-GD2 ANTIBODIES AND METHODS AND USES RELATED THERETO
    Patent Number: JP2011526785-A; Date:2011-10-20
  57. Epstein-Barr virus-Specific Cytotoxic T Lymphocyte Epitope Peptides And The Uses Thereof
    Patent Number: JP2011239787-A; Date:2011-12-01
  58. HSA-Related Compositions and Methods of Use
    Patent Number: JP2013519392-A; Date:2013-05-30
  59. COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
    Patent Number: JP2013544511-A; Date:2013-12-19
  60. PROCESS, VECTORS AND ENGINEERED CELL LINES FOR ENHANCED LARGE-SCALE TRANSFECTION
    Patent Number: EP2285969-A1; Date:2011-02-23
  61. Expression of Hydrophobic Proteins
    Patent Number: JP2006514606-A; Date:2006-05-11
  62. Modified Microbial Nucleic Acid
    Patent Number: JP2009538603-A; Date:2009-11-12